Clinical trials: Obesity & Overweight, open to volunteers
Obesity, Obesity & Overweight
Real-world Exploration of Digital iNnovation in the Management of Excess Weight
This is a real-world study. The purpose of this research is to explore whether a new National Institute for Health and Care Excellence (NICE)-approved digital weight-management model of care can improve health service delivery…
- Trial name
- RENEW (NCT07283978)
- Testing
- Digital Weight Management Programme
- Where
- United Kingdom
- Volunteers
- 580 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Type 1 Diabetes, Overweight , Obesity
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity.
- Trial name
- SEMA-T1D-BODY (NCT07891156)
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Physical Inactivity, Overweight
Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention
This prospective, single-arm interventional study will investigate why adults receiving the same prescribed dose and relative intensity of exercise show divergent changes in energy balance, body weight, and body composition.
- Conditions
- Physical Inactivity, Overweight, Obesity
- Trial name
- NCT07893249
- Testing
- Supervised Aerobic Exercise Programme
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Obesity, Overweight
Improving Glycemic Control With Electrical Stimulation
Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels.
- Conditions
- Obesity, Overweight, Insulin Resistance
- Trial name
- NCT03947697
- Testing
- Neuromuscular Electrical Stimulation (Sensory), Neuromuscular Electrical Stimulation, Resistance Training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Pre Diabetic, Obesity & Overweight
The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity
This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with…
- Trial name
- CGM (NCT07423065)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- 3 sites in Slovenia
- Volunteers
- 34 people
- Sponsor
- University of Primorska
Obesity & Overweight, Childhood
Project GAME ON! A Digital Comic Tool to Promote Healthy Behaviors
This clinical trial aims to evaluate an interactive, culturally relevant digital health promotion comic designed to support healthy dietary and physical activity behaviors among Black/African American and Latino children ages 8…
- Conditions
- Obesity & Overweight, Childhood, Diet Habits, Engagement
- Trial name
- NCT07820735
- Testing
- Web-based customizable comic and newsletters, Didactic health information and newsletters, Web-based comic and newsletters
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Tufts University
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
- Trial name
- NCT07890870
- Testing
- IBIO-610
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity & Overweight
Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity
Glucagon-like peptide (GLP1) drugs have quickly become a standard treatment for the adults with obesity. These drugs target the appetite control center of the brain, which clows the rate of stomach emptying, and makes a person…
- Trial name
- GUT BOOST (NCT07823452)
- Testing
- gut-brain axis (GLP-1)-activating food carbohydrate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Indiana University
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
Obesity &Amp; Overweight
EAT SMART Teen Study
The goal of this controlled trial is to assess the feasability and efficacy of a 12-week mindfulness-based intervention (MBI) in adolescents living with obesity.
- Trial name
- MB-EAT (NCT07130838)
- Testing
- MB-EAT program, Feasibility study, Psychoeducation
- Where
- Canada
- Volunteers
- 170 people
- Sponsor
- Gary Goldfield
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Prediabetes or Overweight, Obesity Type 2 Diabetes Mellitus
Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
This is a multicentre, prospective, observational study of the medicine tirzepatide as it is used in routine clinical care in Pakistan.
- Conditions
- Prediabetes or Overweight, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight
- Trial name
- TRIBUTE-PK (NCT07809568)
- Where
- 9 sites in Pakistan
- Volunteers
- 330 people
- Sponsor
- Universiti Sains Malaysia
Obesity & Overweight
Multimodal Intervention for Weight Management and Health in the Elderly Population
Aging may be accompanied by changes in body composition, muscle strength, metabolic health, and well-being. In older adults with overweight or obesity, strategies that combine physical exercise, behavioral changes, and…
- Trial name
- NCT07820774
- Testing
- Nutritional guidance focused on adopting a high-protein diet., Group Cognitive Behavioral Therapy Intervention, Resistance Training Program
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade Cesumar (UNICESUMAR)
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Obesity, Overweight
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07881887
- Testing
- LY4167586
- Where
- 12 sites in United States, Singapore
- Volunteers
- 617 people
- Sponsor
- Eli Lilly and Company